Tessa Romero
Stock Analyst at J.P. Morgan
(4.41)
# 1,146
Out of 4,405 analysts
187
Total ratings
51.1%
Success rate
14.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UPB Upstream Bio | Downgraded: Hold | $8 | $6.10 | +31.15% | 10 | Jun 12, 2026 | |
| AGIO Agios Pharmaceuticals | Rated: Hold | $31 | $29.46 | +5.23% | 17 | Jun 11, 2026 | |
| NRIX Nurix Therapeutics | Maintained: Buy | n/a | $16.95 | - | 3 | Jun 11, 2026 | |
| SPTX Seaport Therapeutics | Reiterated: Buy | $42 | $18.00 | +133.33% | 2 | Jun 8, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | $97 | $70.15 | +38.28% | 32 | Jun 5, 2026 | |
| EWTX Edgewise Therapeutics | Rated: Buy | $45 → $53 | $34.83 | +52.17% | 21 | Jun 5, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $23 | $11.09 | +107.39% | 4 | Jun 3, 2026 | |
| LRMR Larimar Therapeutics | Initiated Coverage: Buy | $9 | $3.47 | +159.37% | 1 | May 27, 2026 | |
| XENE Xenon Pharmaceuticals | Rated: Buy | $80 → $82 | $52.10 | +57.39% | 15 | May 27, 2026 | |
| NMRA Neumora Therapeutics | Maintained: Sell | n/a | $1.78 | - | 5 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $56 | $44.18 | +26.75% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $2.75 | - | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $38 | $35.95 | +5.70% | 3 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $17 → $16 | $18.19 | -12.04% | 13 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $33 | $13.03 | +153.26% | 6 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $34 | $21.09 | +61.21% | 19 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $11.28 | - | 12 | Dec 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.78 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.37 | - | 3 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $5.66 | n/a | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.68 | n/a | 4 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $10 | $10.44 | n/a | 2 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $32.85 | n/a | 1 | Nov 9, 2020 |
Upstream Bio
Jun 12, 2026
Downgraded: Hold
Price Target: $8
Current: $6.10
Upside: +31.15%
Agios Pharmaceuticals
Jun 11, 2026
Rated: Hold
Price Target: $31
Current: $29.46
Upside: +5.23%
Nurix Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: n/a
Current: $16.95
Upside: -
Seaport Therapeutics
Jun 8, 2026
Reiterated: Buy
Price Target: $42
Current: $18.00
Upside: +133.33%
Cytokinetics
Jun 5, 2026
Maintained: Buy
Price Target: $97
Current: $70.15
Upside: +38.28%
Edgewise Therapeutics
Jun 5, 2026
Rated: Buy
Price Target: $45 → $53
Current: $34.83
Upside: +52.17%
Oculis Holding AG
Jun 3, 2026
Maintained: Buy
Price Target: $23
Current: $11.09
Upside: +107.39%
Larimar Therapeutics
May 27, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $3.47
Upside: +159.37%
Xenon Pharmaceuticals
May 27, 2026
Rated: Buy
Price Target: $80 → $82
Current: $52.10
Upside: +57.39%
Neumora Therapeutics
May 26, 2026
Maintained: Sell
Price Target: n/a
Current: $1.78
Upside: -
May 8, 2026
Maintained: Buy
Price Target: $50 → $56
Current: $44.18
Upside: +26.75%
Apr 2, 2026
Maintained: Sell
Price Target: n/a
Current: $2.75
Upside: -
Mar 24, 2026
Rated: Buy
Price Target: $38
Current: $35.95
Upside: +5.70%
Mar 16, 2026
Maintained: Hold
Price Target: $17 → $16
Current: $18.19
Upside: -12.04%
Mar 10, 2026
Maintained: Buy
Price Target: $26 → $33
Current: $13.03
Upside: +153.26%
Mar 4, 2026
Rated: Buy
Price Target: $31 → $34
Current: $21.09
Upside: +61.21%
Dec 26, 2025
Maintained: Buy
Price Target: n/a
Current: $11.28
Upside: -
Nov 18, 2025
Maintained: Hold
Price Target: n/a
Current: $2.78
Upside: -
Oct 7, 2025
Maintained: Buy
Price Target: n/a
Current: $4.37
Upside: -
Oct 23, 2024
Downgraded: Sell
Price Target: n/a
Current: $5.66
Upside: n/a
Oct 18, 2024
Maintained: Hold
Price Target: n/a
Current: $2.68
Upside: n/a
Jul 13, 2022
Downgraded: Hold
Price Target: $22 → $10
Current: $10.44
Upside: n/a
Nov 9, 2020
Downgraded: Hold
Price Target: n/a
Current: $32.85
Upside: n/a